Sarcoma News

This article reports that the U.S. Food and Drug Administration (FDA) has granted two special designations to SOT106, an experimental

This study focuses on improving how doctors evaluate risk for patients diagnosed with Ewing Sarcoma. Traditionally, doctors relied mostly on

Transition Bio, a biopharmaceutical company specializing in drug discovery, has partnered with the Little Warrior Foundation, a non-profit dedicated to

Ewing sarcoma is an aggressive bone and soft tissue cancer that frequently recurs at distant body sites, leading to poor

The Rutledge Cancer Foundation has awarded a landmark $1.5 million ACES (Accelerating Cures for Ewing Sarcoma) grant to support pioneering

Fannin Partners has secured two major grants from the Congressionally Directed Medical Research Programs (CDMRP) and the Faris Foundation to

This article details a first-in-human case report evaluating a novel therapeutic cancer vaccine. Ewing sarcoma is driven by specific genetic

This systematic review, titled “GD2-targeted immunotherapy in pediatric bone sarcomas: a systematic review of emerging strategies and combination approaches” (published

Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed a promising double-barreled treatment strategy to tackle

The article provides a comprehensive review of advances in treating rare primary bone cancers, such as osteosarcoma, Ewing sarcoma, and